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The cardiac ﬁeld has beneﬁted from the availability of several CaMKII inhibitors serving as
research tools to test putative CaMKII pathways associated with cardiovascular physiology
and pathophysiology. Successful demonstrations of its critical pathophysiological roles
have elevated CaMKII as a key target in heart failure, arrhythmia, and other forms of
heart disease. This has caught the attention of the pharmaceutical industry, which is now
racing to develop CaMKII inhibitors as safe and effective therapeutic agents.While the ﬁrst
generation of CaMKII inhibitor development is focused on blocking its activity based onATP
binding to its catalytic site, future inhibitors can also target sites affecting its regulation by
Ca2+/CaMor translocation to someof its protein substrates.The recent availability of crystal
structures of the kinase in the autoinhibited and activated state, and of the dodecameric
holoenzyme, provides insights into the mechanism of action of existing inhibitors. It is also
accelerating the design and development of better pharmacological inhibitors. This review
examines the structure of the kinase and suggests possible sites for its inhibition. It also
analyzes the uses and limitations of current research tools. Development of new inhibitors
will enable preclinical proof of concept tests and clinical development of successful lead
compounds, as well as improved research tools to more accurately examine and extend
knowledge of the role of CaMKII in cardiac health and disease.
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INTRODUCTION
The search for a multifunctional Ca2+-stimulated protein kinase
serving to coordinate the actions of Ca2+-linked signals, in anal-
ogy to the cAMP-dependent protein kinase (PKA) already known
to coordinate the actions of cAMP, led to the discovery and charac-
terization of multifunctional Ca2+/calmodulin (CaM)-dependent
protein kinase II (CaMKII; reviewed in Hudmon and Schulman,
2002; Swulius and Waxham, 2008). Delineation of its functions
and relevant substrates was initially complicated by the fact that
its activator, Ca2+/CaM, regulates many other enzymes. It has
therefore been pharmacological inhibitors and genetic ablation or
suppression of CaMKII activity that have served to deﬁne its func-
tions. This review aims to provide the context for understanding
protein kinase inhibition and speciﬁcally to describe the types of
inhibitors used, their advantages, and their disadvantages. There
is now the potential for better inhibitors as therapeutic agents
and research tools stemming from industry interest in pursuing
CaMKII-based therapeutics, due in no small measure to the car-
diovascular scientists in this issue who have identiﬁed its critical
role in cardiac disease.
CaMKII STRUCTURE
Among Ca2+/CaM-dependent kinases CaMKII can be best
claimed as the multifunctional CaM kinase because it has broad
substrate speciﬁcity and is ubiquitous, with the γ and δ isoforms
present in heart, brain, and other tissues and α and β present
at very high levels in brain. Each of these four genes give rise
to multiple isoforms, primarily by alternatively spliced sequences
(Hudmon and Schulman, 2002; Tombes et al., 2003). The most
distinctive feature of CaMKII among protein kinases is that it
self-assembles into supramolecular structures of twelve subunits.
Each subunit contains an N-terminal catalytic domain followed
by a regulatory segment of approximately 40 residues that serves
an autoinhibitory function by blocking access to the catalytic
site. This domain organization is typical of CaM-regulated pro-
tein kinases. The regulatory segment (or autoinhibitory domain)
contains most of the elements that are critical for regulation of
activity; the posttranslational modiﬁcation (PTM) segment for
regulation by autophosphorylation (Thr287), O-GlcNAC mod-
iﬁcation (Ser280), and oxidation (Met281/Met282), and the
CaM-recognition sequence (Figure 1). We will use the amino
acid numbering based on the sequence of CaMKIIδ, which
are one higher than for the α isoform. Unique to CaMKII is
the C-terminal hub or association domain, which is responsi-
ble for subunit oligomerization into dodecameric holoenzymes.
A ﬂexible linker of variable length connects the regulatory seg-
ment to the association domain and it is where most variability
resides.
The high resolution crystal structures of the autoinhibited
kinase domain and regulatory segment of C. elegans CaMKII
(Rosenberg et al., 2005) and of all four human isoforms (Rellos
et al., 2010) have been elucidated. The structures show a canoni-
cal kinase fold with an N-terminal lobe (N-lobe) connected by a
“hinge” segment to a C-terminal lobe (C-lobe), where the peptide
or protein substrate binding site resides. The ATP-binding site is
located at the interface between the two lobes in close proximity to
thepeptide substrate binding site. In these autoinhibited structures
the regulatory segment forms an α-helix of various lengths and
folds back onto the kinase domain blocking access to the catalytic
site (Figure 1). The critical autophosphorylation site, Thr287,
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FIGURE 1 | CaMKII domain organization and schematic of activation
states. One subunit of a holoenzyme composed of hub and bi-lobed catalytic
domain is shown in the inactive conformation. The autoinhibitory domain or
regulatory segment contains the PTM segment, important for regulation by
phosphorylation, oxidation, and GlcNAcylation, followed by the CaM binding
domain. Binding of Ca2+/CaM displaces the autoinhibitory domain leading to
rearrangement of the lower or C-lobe of the kinase allowing substrate access
to the catalytic cleft and the phosphoacceptor site A, and formation of
docking sites B/C that can also be used for substrate speciﬁcity. Regulatory
modiﬁcations at PTM segment by either Ca2+/CaM-stimulated
autophosphorylation, e.g., by β-adrenergic stimulation or rapid heart rate (HR),
oxidation by ROS, e.g., by Angiotensin II signaling, or GlcNAcylation by
hyperglycemia disable the autoinhibitory domain to generate a persistently
active or “turbocharged” CaMKII leading to cardiac pathophysiology.
is buried at the base of the regulatory segment and inaccessible
for phosphorylation. Ca2+/CaM binding to the regulatory seg-
ment has therefore the dual purpose of ﬁrst facilitating access
to the active site of the kinase by displacing the regulatory seg-
ment, and second, to make Thr287 available for phosphorylation
in trans by a neighboring activated kinase subunit (Hanson et al.,
1994). Phosphorylation of Thr287 likely impairs the rebinding
of the autoinhibitory domain (Colbran et al., 1989) rendering the
kinase “autonomous”of Ca2+/CaM and constitutively active until
dephosphorylated (reviewed in Hudmon and Schulman, 2002).
The activated state seen in a crystal structure of the kinase
domain with the regulatory segment displaced from the kinase
domain and bound to Ca2+/CaM sheds light on the process
of activation by CaM (Rellos et al., 2010). The most notable
structural rearrangement is a major reorganization of a heli-
cal segment in the C-lobe of the kinase, helix αD (Figure 1),
impeding the rebinding of the CaM-displaced regulatory seg-
ment. The positional shift in helix αD results in the reorientation
of Glu97, an important ATP-coordinating residue, leading to a
conformation improved for ATP-binding and catalysis (Rosen-
berg et al., 2005; Rellos et al., 2010). An interesting feature of
this “activated” structure is that the regulatory segment adopts
an extended conformation and positions Thr287 for capture
and autophosphorylation by the active site of a neighboring
kinase, as similarly seen in some of the C. elegans structures
(Chao et al., 2010).
Studying activation states can give insights to additional strate-
gies for inhibitor design (see below). The phosphoacceptor
sequence in substrates is positioned at docking site A (previ-
ously termed S-site; Figure 1; Chao et al., 2010) and has been
used in the design of peptide substrates and of “pseudosubstrate”
peptides used as inhibitors. An important consequence of helix
αD reorientation is the creation of a hydrophobic pocket (ﬁrst
identiﬁed and termed docking site B by Chao et al., 2010) that is
absent in the autoinhibited form of the kinase. This site anchors
hydrophobic residues located ﬁve to eight residues N-terminal
to the phosphoacceptor site of some substrates for added speci-
ﬁcity, and is used for intracellular targeting of the kinase and by
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peptide inhibitors such as CaMKIINtide (see below). Similarly, an
acidic pocket at the base of the C-lobe designated docking site C
provides additional interactions for orienting interacting proteins
(Chao et al., 2010; Figure 1). Docking sites B/C correspond func-
tionally to the region of the molecule referred to as the T-site in
previous studies of the autoinhibited state (Hudmon and Schul-
man, 2002 and references therein). Referring to these as docking
sites B and C is now preferred because the site is not just vacated
by the regulatory segment during activation but is altered in the
process.
The holoenzyme is assembled as two hexameric rings symmet-
rically stacked one on top of the other with the kinase domains
arranged peripherally around a central hub (Woodgett et al., 1983;
Kolodziej et al., 2000; Morris and Torok, 2001; Chao et al., 2011).
In an isoform lacking the linker domain, the kinase domains nes-
tle between two hub domains with their active sites and regulatory
segments completely inaccessible toCa2+/CaM. It is proposed that
a dynamic equilibrium governed by the linker length between the
kinase and the association domains regulates exposure to CaM-
binding sites facilitating the process of holoenzyme activation
(Chao et al., 2011).
The PTM segment that enables autonomous activity fol-
lowing autophosphorylation evolved to extend such regulation
to reactive oxygen species (ROS) and glucose-linked signaling
(Figure 1). Increased ROS leads to oxidation of Met 281/282
at the base of the regulatory segment (Erickson et al., 2008).
Elevated glucose leads to covalent modiﬁcation of CaMKII
nearby at Ser280 by O-linked N-acetylglucosamine (GlcNAcy-
lation; Erickson et al., 2013). Introduction of bulky groups to
the region normally interacting with the surface of the C-lobe
is expected to weaken the interaction between the two and, like
Thr287 phosphorylation, keep the autoinhibitory domain dis-
placed and the kinase persistently active (Figure 1). All three
modiﬁcations, individually and together, can produce a “tur-
bocharged” kinase with consequences for arrhythmia (Chelu
et al., 2009; Purohit et al., 2013), heart failure (Anderson et al.,
2011; Luo et al., 2013), asthma (Sanders et al., 2013), and dia-
betes (Erickson et al., 2013). There may also be additional
PTM of CaMKII involving nitrosation of Cys (Gutierrez et al.,
2013).
Taken together, the recent accumulation of structural informa-
tion offers a clearer understanding of CaMKII regulation. These
structures not only provide a foundation for the rational design
and optimization of CaMKII-speciﬁc inhibitors but may also
present the opportunity for novel inhibitor-design strategies that
extend beyond ATP-binding sites.
CaMKII INHIBITORS: FROM BENCH TO CLINIC
KN-93/KN-62
The most widely used inhibitor for study of cellular and in
vivo functions of CaMKII has been KN-93 (Sumi et al., 1991;
Figure 2A). It is one of a remarkable number of tool inhibitors
developed by Hidaka and his colleagues for PKA, protein kinase C
(PKC),CaMKII, andMLCK,many of which became commercially
available and widely used. However, these were not on the path
to therapeutic use and are therefore not optimized for potency,
selectivity, or pharmacokinetics. KN-93 supplanted KN-62 which
shares structural elements and mechanism of action (Tokumitsu
et al., 1990). Inhibition by both is competitive with Ca2+/CaM
and not competitive with ATP. KN-62 binds to the holoenzyme
and interferes with the ability of Ca2+/CaM to activate it, but
does not directly bind to CaM, i.e., it is not a CaM antagonist
at effective inhibitory concentrations. It is worth noting, how-
ever, that a “predecessor” of KN-93 with a very similar structure,
HMN-709, is a CaM antagonist (Yokokura et al., 1996; Figure 2A).
Neither KN-62 nor KN-93 inhibits the activity of autophospho-
rylated CaMKII, consistent with a block of activation but not of
catalysis (Tokumitsu et al., 1990; Sumi et al., 1991). Such inhibi-
tion can be classiﬁed as “ATP non-competitive” or “allosteric” as
binding likely occurs outside the active site. Based on an ischemic
stroke model, it has been suggested previously that blocking cat-
alytic activity is the more effective approach because autonomous
activity is resistant to allosteric inhibition by KN-93 (Vest et al.,
2010). The observed differing efﬁcacies, however, may have
been due to differences in inhibitor concentrations at the site of
action.
KN-93 (and KN-62) likely blocks the ability of Ca2+/CaM to
wrap around the CaM-binding segment and free it from the cat-
alytic domain. The displacement of the autoinhibitory regulatory
segment can be monitored by appropriate FRET pairs and indeed
KN-93 blocks the change in FRET signal induced by Ca2+/CaM
and the change promoted by either autophosphorylation, oxida-
tion, or GlcNAcylation (Erickson et al., 2011, 2013). KN-93 blocks
Ca2+/CaM from displacing and “presenting” Thr287 to an active
neighboring subunit for phosphorylation (Rich and Schulman,
1998). KN-93 similarly blocks presentation of Ser280 for GlcNA-
cylation (Erickson et al., 2013). Once activated and autophospho-
rylated, however, KN-93 does not inhibit the kinase, nor is it
likely to inhibit kinase made autonomously active by oxidation or
GlcNAcylation.
The initial characterization of KN-93 and KN-62 showed them
to be selective for CaMKII relative to PKA, PKC andMLCK (Toku-
mitsu et al., 1990; Sumi et al., 1991), but they were later shown to
inhibit CaMKI and CaMKIV equally well (Mochizuki et al., 1993;
Enslen et al., 1994). KN-93 is not very potent, inhibiting CaMKII
with an IC50 ∼1–4 μM depending on level of CaM and other
assay conditions (Sumi et al., 1991; Anderson et al., 1998; Reza-
zadeh et al., 2006). A recent screen against 234 protein kinases
shows that KN-93 is indeed very selective, but its targets now
include Fyn, Haspin, Hck, Lck, MLCK, Tec, and TrkA (Gao et al.,
2013).
Tool inhibitors are rarely optimized for potency or off-target
effects and indeed KN-62 and KN-93, while inhibiting only a few
protein kinases, do inhibitmany of the ion channels that have been
tested. KN-62 and KN-93 block modulation of the L-type Ca2+
channel by CaMKII but also have direct effects on the channel (Li
et al., 1992; Anderson et al., 1998) so it is important to use their
kinase-inactive controls (KN-04 and KN-92). KN-62 and KN-93
block macroscopic voltage-dependent K+ current (Kv) in smooth
muscle cells at concentrations (0.3–3 μM) used to inhibit CaMKII
(Ledoux et al., 1999). KN-92 similarly blocks the channel and is
therefore useful in excluding K+ channel effects. A detailed analy-
sis demonstrated that KN-93, but not KN-92, blockedmembers of
the Kv1, Kv2, Kv3, Kv4, and Kv7 (hERG) voltage-gated potassium
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FIGURE 2 | Chemical structures of CaMKII inhibitors. (A) The ATP
non-competitive inhibitors and controls are: KN-93 (Sumi et al., 1991);
KN-92 (Tombes et al., 1995); KN-62 and KN-04 (Ishikawa et al., 1990)
HMN-709 (Yokokura et al., 1996). (B) Computational docking of
Compound 15b (Mavunkel et al., 2008) illustrates interaction of an ATP
competitive inhibitor viewed from the solvent front and shown docked
at the kinase “hinge” and interaction at the hydrophobic pocket. The
structure of Compound 15b is shown, with the same orientation, with
residues that interact at the hinge in blue based on either a crystal
structures (Bosutinib) or based on modeling when a reasonable docked
structure could be obtained. The compounds above are: Scios-15b
(Mavunkel et al., 2008); Bosutinib (Chao et al., 2011); Sanoﬁ-32
(Beauverger et al., 2012); Dainippon A: 8p (Asano et al., 2010); Dainippon
B: 25 (Komiya et al., 2012); Rimacalib/SMP-114 (Westra et al., 2010).
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channel families at concentrations that also block CaMKII (Reza-
zadeh et al., 2006). To be broadly useful as a control, it would be
ideal if KN-93 and KN-92 had the same pharmacology other than
for CaMKII, but this is unfortunately not the case. For example,
KN-92 is not as potent in direct inhibition of L-typeCa2+ channels
as is KN-93 (Anderson et al., 1998) or as potent in direct inhibition
of IP3-induced Ca2+ release via IP3R-1 (Smyth et al., 2002) and
thus not every effect blocked by KN-93 and not by KN-92 can be
ascribed to CaMKII. Despite these caveats, these inhibitors have
been extremely useful as initial evidence for CaMKII action, as
illustrated by several examples in Table 1.
It is a bit surprising, given the channel blocking effects of KN-
93, that it has not been as problematic to use it for in situ inhibition
of CaMKII,when compared to peptide inhibitors below. The inter-
play between its effect on K+ channels and L-type Ca2+ channels
and inhibition of CaMKII are not well understood and com-
plicate arrhythmia studies. Clearly, modiﬁcation of K currents,
such as in genetic mutations, can lead to arrhythmia, whereas
ablation or peptide inhibition of CaMKII are anti-arrhythmic.
KN-93 may therefore be anti-arrhythmic despite its K+ channel
blockade because concurrent inhibition of CaMKII serves as an
arrhythmia shield that blocks the pro-arrhythmic consequence
of the K+ channel inhibition. Alternatively, a signiﬁcant com-
ponent of the anti-arrhythmic effect of KN-93 could be to reduce
CaMKII activation by inhibiting the L-typeCa2+ channel and low-
ering freeCa2+ levels. Ultimately, inhibition of CaMKIIwith small
molecule allosteric or ATP competitive inhibitors can be achieved
without a signiﬁcant K+ channel component, something that is
harder to achieve with channel blockers used as anti-arrhythmic
agents.
SUBSTRATE-BASED INHIBITORS: AUTOCAMTIDE-3 INHIBITOR
(AC3-I)/AUTOCAMTIDE-2 INHIBITOR PROTEINS (AIP)
Identiﬁcation of the autoinhibitory regulatory segment of
CaMKIIα led to development of long inhibitory peptides lack-
ing the CaM binding sequence (residues 273–302) that could be
injected into cells, e.g., implicating CaMKII in functions such as
long-term potentiation (Payne et al., 1988; Malinow et al., 1989).
The N-terminal end of this peptide contains the autophospho-
rylation site that was the basis for peptides substrates such as
autocamtide-2 and autocamtide-3 (Hanson et al., 1989) and sub-
stitution of the phosphorylatable Thr to an Ala generated the
Table 1 | CaMKII inhibitors and related compounds.
Inhibitor type Controls/verification Action of inhibitor
KN-93/KN-62 KN-92; GFP-AC3-I transgene KN-93 blocked pacing induced atrial ﬁbrillation in the Ryr2R176Q/+ mouse model (Chelu et al., 2009).
KN-92; AIP; CaMKIIδ knockout KN-93, AIP, and knockout block cardiac arrhythmogenesis and sarcoplasmic reticulum Ca2+ leak
(Sag et al., 2009).
KN-92 KN-93 and AIP were used to demonstrate that CaMKII is linked to SAN cell bioenergetics, affecting
both ATP consumption and ATP generation (Yaniv et al., 2013).
KN-92; CaMKIIδ knockout KN-93 blocks increase in GlcNAcylation-dependent Ca2+ spark frequency and prevents premature
ventricular complexes also seen in diabetes (Erickson et al., 2013).
AC3-I/AIP GFP-AC3-C Myocardial GFP-AC3-I transgene blocked maladaptive remodeling following chronic β-adrenergic
stimulation or myocardial infarct with GFP-AC3-I (Zhang et al., 2005).
GFP-AC3-C;KN-93/KN-92 Myocardial GFP-AC3-I transgene in calcineurin hypertrophy model primarily reduced ventricular
arrhythmias, improved mechanical function, and decreased mortality with minimal effect on the
hypertrophic phenotype (Khoo et al., 2006).
GFP-AC3-C AngII promoted AF was blocked by GFP-AC3-I and prevented by knockins with oxidation resistant
CaMKII(MM > VV) or RyR2 lacking CaMKII phosphorylation site (RyR2S2814A; Purohit et al., 2013).
GFP-AC3C; CaMKIIN Myocardial GFP-AC3-I and blocked increase mortality of diabetic mice after myocardial infarction via
reactive oxygen species and conﬁrmed with CaMKII(MM > VV) mice (Luo et al., 2013).
CaMKIIN Myocardial GFP-AC3-I and -AC3-C GFP-CaMKIIN (sinoatrial node expressed) blocked isoproterenol-stimulated CaMKII activation and
reduced the ﬁght or ﬂight heart rate response to stress or isoproterenol (Wu et al., 2009).
GFP; AC3-I GFP-CaMKIIN (sinoatrial node expressed) blocked AngII and ROS activation of CaMKII and cell
death contributing to sinus node dysfunction (Swaminathan et al., 2011).
AC3-I; shRNA; KN-93 HA-CaMKIIN targeted to cytoplasmic membranes acts outside the nucleus to mediate induction of
complement factor B following myocardial infarct (Singh et al., 2009).
CaMKII (Thr287Asp) mtCaMKIIN (with mitochondrial localization sequence) and palmitoyl-CaMKIIN for membrane
localization support a role of mitochondrial CaMKII in ischemia reperfusion injury, MI and
neurohumoral injury due to increased inner membrane mitochondrial Ca2+ uniporter current
(Joiner et al., 2012).
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peptide inhibitors AIP (Ishida et al., 1995) and AC3-I (Braun and
Schulman, 1995). They inhibit CaMKII with >100-fold selectivity
relative to PKC, PKA and CaMKIV, although their selectivity has
not been broadly proﬁled, e.g., green ﬂuorescent protein (GFP)-
AC3-I was found to inhibit cellular actions of protein kinase D1
(PKD1) aswell as those of CaMKII (Backs et al., 2009). As exempli-
ﬁed in Table 1, peptide inhibitors with internalization sequences
for cellular studies or the transgenic expression of the peptides
in mice have been critical ﬁrst steps in delineating cardiovascular
functions of CaMKII. Transgenic expression of inhibitor/control
pairs can also be used to delineate molecular pathways of gene
expression (Singh et al., 2009) and phosphorylation initiated by
CaMKII activation (Scholten et al., 2013).
Some caution is warranted in the use of peptide (or small
molecule) inhibitors that are often optimistically described as
“highly speciﬁc inhibitors” when experience or data should sug-
gest otherwise. Useful ﬁrst generation tool inhibitors are typically
developed by academic labs with limited resources, so selectiv-
ity is based on a handful of kinases available to the lab rather
than on the 50–300 kinases that should be tested. As a min-
imum, the off-target effects of AC3-I should be checked by
use of a control peptide (AC3-C; Patel et al., 1999; Wu et al.,
2009). Altered selectivity can also occur when peptides are fused
to GFP in order to increase expression and metabolic stabil-
ity, or modiﬁed by lipids or internalization sequences for cell
permeation. For example, addition of Ant (Antennapedia) to
another peptide inhibitor generated a direct CaM antagonistic
sequence (Buard et al., 2010) and myristoylated AIP and AC3-C
were shown to have some effects unrelated to CaMKII inhibition
(Wu et al., 2009).
CaMKIIN (CaM-KIIN)
CaMKIIN or CaM-KIIN designates small endogenous proteins
that inhibit CaMKII with high afﬁnity that can be applied
pharmacologically or genetically. CaMKIIN was discovered by
use of a yeast two-hybrid screen whereby the catalytic domain
of CaMKIIβ served as bait to clone interacting proteins from
a rat neuronal library (Chang et al., 1998, 2001). Two small
proteins sharing high homology were identiﬁed and termed
CaM-KIINβ (79 amino acids) and CaM-KIINα(78 amino acids)
to designate them as inhibitors, and often spelled CaMKIIN.
The α and β in their names are unrelated to the CaMKII iso-
form, as either of these inhibits all CaMKII isoforms with
IC50 of 50 nM (Chang et al., 2001). The protein has not
been detected in heart although a related mRNA was detected
(Zhang et al., 2001).
Identiﬁcation of the core inhibitory domain of CaMKIIN
led to generation of a 28 amino acid peptide inhibitor termed
CaMKIINtide (Chang et al., 1998) that was subsequently short-
ened and modiﬁed to improve potency (Vest et al., 2007; Coultrap
and Bayer, 2011; Gomez-Monterrey et al., 2013). CaMKIIN and
CaMKIINtide only bind to the activated conformation of CaMKII,
suggesting that they dock to the kinase surface exposed and shaped
only after displacement of the autoinhibitory domain during acti-
vation. They should therefore inhibit CaMKII activated by bound
Ca2+/CaM or autonomously active due to autophosphorylation,
methionine oxidation, or GlcNAcylation. A 21-residue segment
of CaMKIINtide was co-crystallized with CaMKII and shown to
dock at the B/C sites using hydrophobic and basic residues at
its N-terminal region to support potency and speciﬁcity and to
extend to the A site where it precludes substrate from binding in a
manner similar to protein kinase inhibitor (PKI) binding to PKA
(Chao et al., 2010; Figure 1).
CaMIINtide has been modiﬁed to increase potency (Coultrap
and Bayer, 2011; Gomez-Monterrey et al., 2013). In one series of
optimizations, a shorter sequence of 21 amino acids (CN21a) was
found to retain the potency of CaMKIINtide (Vest et al., 2007).
A 19 amino acid sequence was then subjected to Ala scanning
substitutions to identify critical residues and subsequent modiﬁ-
cations produced a more potent and selective CaMKII inhibitor
termed CN19o (Coultrap and Bayer, 2011). CN19o inhibited
CaMKIIα with IC50 < 0.4 nM and improved selectivity for
tested kinases, showing minimal or no inhibition at 5 μM against
CaMKI, CaMKIV,DAPK1, AMPK, PKC, and PKA. A similar study
generated a smaller optimized 17 amino acid peptide, CN17β,
with IC50 of 30 nM and little inhibition of CaMKI or CaMKIV
(Gomez-Monterrey et al., 2013).
CaMKIIN and CaMKIINtides are excellent experimental tools
being adopted by the ﬁeld but their use can result in additional
effects by blocking interaction of CaMKII with some anchoring
proteins and substrates that share the B/C docking sites (Figure 1).
Translocation and docking to anchoring proteins aids in ﬁdelity of
signal transduction that would be disrupted byCaMKIIN andmay
generate secondary effects because anchoring proteins often clus-
ter several signaling proteins thatmight be affected (Colbran,2004;
Schulman, 2004; Tsui et al., 2005). Mutations at the B/C sites block
both binding of CN21a and CaMKII translocation/docking to the
glutamate NR2B receptor (Leonard et al., 1999; Strack et al., 2000;
Bayer and Schulman, 2001; Bayer et al., 2006; Vest et al., 2007)
suggesting overlapping binding sites. Application of TatCN21 on
neurons inhibits the kinase but also reduces the level of kinase
at synaptic sites (Sanhueza et al., 2011), decreases clustering in
dendrites, and produces aggregates with polyribosomes (Tao-
Cheng et al., 2013). CaMKIINtides also block interaction with
densin (Jiao et al., 2011) and Cav2.1 calcium channels (Magupalli
et al., 2013) and possibly with βIV-spectrin and other proteins
(Hund et al., 2010). Finally, the biological function of CaMKIIN
is not fully understood and it may directly affect cellular path-
ways unrelated to CaMKII inhibition or interference with its
translocation.
The cardiovascular ﬁeld has appropriately advanced from the
AC3-I/AIP- to CaMKIIN-based inhibitors to delineate in situ
and in vivo functions (Table 1). The inhibitor can be directly
introduced in a regionally selective manner via locally applied
adenoviral constructs, as a transgene targeted to selective tissues,
and even directed to distinct intracellular sites with appropriate
targeting sequences.
ERA OF SMALL MOLECULAR THERAPEUTICS
The inhibitory agents and approaches described above have been
essential in identifying key roles of CaMKII in health and disease
and make a compelling case for targeting CaMKII for several car-
diovascular indications, so as one of us asked previously, “where
are the drugs?” (Anderson et al., 2006). While it is possible that
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a CaMKIIN-based inhibitor could be developed as a therapeutic,
e.g., for local expression at the sinoatrial node (SAN), new small
molecule inhibitors will be needed for treating cardiovascular dis-
ease, and these will, in turn, provide better tools for advancing
CaMKII research. The period covered since the review above has
seen a large increase in the number of protein kinases targeted
in oncology, with over 100 hundred in clinical development and
many in clinical practice (Cohen and Alessi, 2013). The cardiovas-
cular ﬁeld, largely because of the greater safety requirements but
also because of decades-long investments in ion channel blockers,
has been slower in turning to this target class. Themessage emerg-
ing from data published by the CaMKII research ﬁeld has been
heard and now there are several programs targeting CaMKII for
cardiovascular indications.
One of the early programs was initiated at Scios, expanded fol-
lowing its acquisition by Johnson and Johnson, and discontinued
along with more advanced programs for strategic reasons when
Scios was closed. The program did provide some potent ATP
competitive inhibitors, along with structure – activity relation-
ships that enables an understanding of how to inhibit CaMKII
(Lu et al., 2008; Mavunkel et al., 2008). One of the lead com-
pounds, a pyrimidine (Scios 15b) with IC50 of 9 nM in vitro and
320 nM in situ, is shown in Figure 2B. Bosutinib (and sunitinib)
were developed as ATP competitive inhibitors of protein tyrosine
kinases but have surprising potency at inhibitingCaMKII and a co-
crystal of CaMKII with bosutinib has been published (Chao et al.,
2011). Dainippon Sumitomo Pharma has had the most advanced
CaMKII program and developed Rimacalib (SMP-114) for treat-
ment of rheumatoid arthritis. It passed the Phase I safety trial,
but appears not to have shown efﬁcacy in a 24-week Phase II
trial (Tagashira and Fukushima, 2008; Westra et al., 2010). The
other compounds are all potent (2–60 nM) inhibitors generated
during CaMKII inhibition programs at Sanoﬁ (Beauverger et al.,
2012) and Dainippon (Asano et al., 2010; Komiya et al., 2012).
Allosteros Therapeutics is developing both ATP-competitive and
allosteric or ATP non-competitive inhibitors for cardiovascular
and other indications and a CaMKII program at Myogen (with
Novartis) was part of an acquisition by Gilead with no publi-
cations of structures so far. We are aware of several other early
stage CaMKII inhibitor programs and anticipate that both tool
inhibitors for academic research as well as new chemical entities
for treating cardiovascular disease will arise from several of these
programs.
The biochemical properties of some the best characterized
CaMKII inhibitors are summarized in Table 2.
INHIBITOR DESIGN
CaMKII is now accepted as a key target in cardiovascular disease
and the focus is shifting to creation of selective inhibitors that are
safe and effective for therapeutic use. The global market for kinase
inhibitors is over $30B, mostly targeting protein tyrosine kinases
with both biologics and small molecules. Structure-guided drug
design and virtual library and fragment screening are likely to ben-
eﬁt from the recent availability of high resolution crystal structures
of CaMKII in various conformations. Targeting the ATP-binding
site is the most common approach with small molecule inhibitors;
however, speciﬁcity becomes a challenge because there are over
500 kinases whose active conformation of the site have a simi-
lar shape and amino acid composition. Their potency must also
be very high in order to compete with millimolar levels of cel-
lular ATP. Successful development of ATP competitive inhibitors
for oncology indications has demonstrated that appropriate selec-
tivity is achievable. The ﬁrst generation of CaMKII therapeutics
will likely target the ATP-binding site because of the large body
of structural information and medicinal chemistry experience
that facilitates the design of relatively selective ATP competitive
inhibitors.
The role of CaMKII in cognitive memory and neuronal plas-
ticity that involves its α and β isoforms in brain necessitates
development of inhibitors do not block these isoforms in brain,
certainly when intended for long-term or chronic use. One
approach is gene therapy with viral vectors for expression of pep-
tides or proteins, such as SERCA2a or S100A1 to the heart or
speciﬁc or very localized regions of heart, such as SAN by intra-
coronary application or endocardial injection by catheter (Pleger
et al., 2013). This type of approach for CaMKII inhibitory pro-
teins, coupled with cardiac-selective promoters, would minimize
expression outside the heart and would certainly avoid expression
in brain. However, widespread adoption will need to await suc-
cessful and safe demonstration of exemplary cardiac gene therapy
Table 2 | Biochemical properties of best characterized CaMKII inhibitors.
Inhibitor Mechanism of action Autonomousa kinase
inhibition
Off-target effects
KN-93, KN-62 Allosteric, CaM-competitive No CaMKI, CaMKIV, ion channels
AC3I/AIP Peptide substrate-competitive Yes PKD-1 in cells
CaMKIIN Peptide substrate/regulatory domain-competitive Yes None identiﬁed
Small molecule
inhibitors (Scios 15b,
SMP-114, Bosutinib)
ATP-competitive Yes Inhibit other ser/thr and tyr kinases in vivo
aAutonomy is based on Thr287 autophosphorylation but results are likely the same for autonomy generated by regulatory domain methionine oxidation or by
GlcNAcylation.
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such gene therapy on a larger scale. Gene therapy still holds great
promise. For CaMKII inhibition, it promises a lower threshold for
success in attaining limiting exposure to heart and avoiding effects
in brain and other organs, but it still has a much higher thresh-
old in the development and regulatory path than development of
small molecule inhibitors.
For small molecule inhibitors inhibition of α- and β-CaMKII
in brain can be minimized by reducing CNS penetration through
optimization of their pharmacokinetic properties. There is a large
body of literature of physical and structural properties that either
promote or limit CNS penetration and typically there are sites on
themolecules not involved in target binding that are optimized for
solubility, plasma protein binding, and CNS penetration. In addi-
tion, while the ATP-binding pockets of the four CaMKII isoforms
are similar, it should be possible to further reduce CNS action by
perhaps a 10-fold selectivity for δ- over α- and β-CaMKII. The β
isoform, in particular, has a slight folding down of the phosphate-
binding loop as well as a bulkier amino acid side chain not seen in
the other three isoforms making it possible to achieve signiﬁcant
discrimination for this isoform.
A strategy designed to circumvent the high redundancy asso-
ciated with kinases in the active conformation is to target the
more diverse inactive conformation (Huse and Kuriyan, 2002).
The anti-cancer drug imatinib (Gleevec®) exhibits a high degree
of selectivity for its target Bcr-Abl because, in addition to partially
occupying the ATP-binding site, it recognizes a distinctive con-
formation of the “activation” loop seen only in the inactive state
(Schindler et al., 2000; Nagar et al., 2002). It is more difﬁcult to use
this strategy for CaMKII because theATP-binding site is not so dif-
ferent in the active and inactive states. However, becauseCaMKII is
subjected to complex and multilayered mechanisms of regulation,
inhibition strategies extending beyond the ATP-binding pocket
may be possible.
Allosteric inhibitors, molecules that inhibit enzyme function
by binding outside of the active site, show higher selectivity pro-
ﬁles for their targets because such sites are not conserved or even
broadly present in the kinome. KN-93 and KN-62 appear to be
allosteric inhibitors that may stabilize the interaction between the
autoinhibitory regulatory segment and kinase domain and may
thereby hinder activation by Ca2+/CaM (Figure 1). Although the
novelty of their unidentiﬁed binding sites makes it more chal-
lenging to optimize allosteric inhibitors, they offer the advantage
of greater selectivity and binding unaffected by high cellular ATP
concentrations.
Selectivity would be most easily achieved at unique sites on the
kinase. For example, docking sites B/C uncovered in the recent
crystal structures may be amenable to medicinal chemistry (Chao
et al., 2010; Figure 1). It may be possible to block some CaMKII
signaling by blocking its targeting to anchoring proteins via the
B/C sites as blocking anchoring candecrease phosphorylation even
if catalytic activity is not blocked (Tsui et al., 2005). Additionally, it
may be possible to achieve target speciﬁcity by blocking exposure
of the site on substrates or anchoring proteins that interacts with
the B/C site. In that case only one or a subset of the multiple
CaMKII substrates would be affected. In many cases, however,
the phosphorylation site on kinase substrates tends to be exposed,
making it difﬁcult to block with a small molecule inhibitor.
Themost unique region of CaMKII is the linker region between
the catalytic and hub domains (Tombes et al., 2003). Linker length
affects the equilibrium between compact and extended holoen-
zyme conformations and the sensitivity of the kinase to the
frequency of Ca2+ pulses (Bayer et al., 2002; Chao et al., 2011).
Thus, in principle, CaMKII inhibition can be achieved by favoring
a more compact holoenzyme and reducing its Ca2+ sensitivity.
It is likely that the ﬁrst generation of CaMKII therapeutics will
be ATP competitive inhibitors with others following that exploit
more unique sites thus enabling fewer off-target effects and safer
use for more chronic and less severe indications.
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